Trial reportScientific reports2026
Evaluating the antioxidant and anti-inflammatory effect of melatonin in pediatric hemodialysis patients: a randomized, placebo-controlled trial.
Trial report in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05570526 (Effect Of Melatonin On The Clinical Outcome In Pediatric Hemodialysis Patients), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Effect Of Melatonin On The Clinical Outcome In Pediatric Hemodialysis Patients
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Children undergoing chronic hemodialysis are exposed to persistent oxidative stress and systemic inflammation, contributing to long-term cardiovascular complications. Melatonin (MLT) is a pleiotropic hormone with potential antioxidant and anti-inflammatory effects. Due to scarcity of studies on pediatrics this study sought to investigate the effects of MLT on oxidative stress and inflammation in pediatric hemodialysis patients. This prospective, block-randomized, double-blinded, placebo-controlled study aimed at assessing the effect of 5 mg MLT on oxidative stress and inflammation in pediatric hemodialysis patients. Forty eligible patients were randomly allocated into either MLT or placebo group. Serum malondialdehyde (MDA), nuclear factor kappa B (NF-κB) levels and lipid profile were measured at baseline and at the end of the study after 12 weeks. MLT significantly reduced the median percent change of serum NF-κB - 5.404(- 58.25-129.7) with p-value = 0.027 in addition to reduction in median total cholesterol in the MLT group from 163.7(134.5-259.5) at baseline to 144(113-242) at the end of the study with p-value = 0.038 and reduction of low-density lipoprotein levels from 96(78-183) to 78.5(48-171) at the end of the 12 weeks with p-value = 0.002 while there was no significance in the placebo group. Although, there was no statistical significance in serum MDA levels in the MLT group but significant increase in MDA levels in the placebo group was detected. MDA levels increased from 11.79 ± 5.078 to 14.79 ± 4.257 at the end of the study in the placebo group with p-value = 0.048, supplementation appears to have beneficial effects on ameliorating inflammation and reducing serum lipids. Moreover, MLT may have a protective antioxidant effect by reduction and inhibition of elevation of serum MDA levels.Trial registration: The study was registered on ClinicalTrials.gov (identifier: NCT05570526 https://clinicaltrials.gov/study/NCT05570526 ), on 6th of October 2022.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.